These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 10428733)
1. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Yoshida H; Shiratori Y; Moriyama M; Arakawa Y; Ide T; Sata M; Inoue O; Yano M; Tanaka M; Fujiyama S; Nishiguchi S; Kuroki T; Imazeki F; Yokosuka O; Kinoyama S; Yamada G; Omata M Ann Intern Med; 1999 Aug; 131(3):174-81. PubMed ID: 10428733 [TBL] [Abstract][Full Text] [Related]
2. Interferon therapy does not prevent hepatocellular carcinoma in HCV compensated cirrhosis. Testino G; Ansaldi F; Andorno E; Ravetti GL; Ferro C; De Iaco F; Icardi G; Valente U Hepatogastroenterology; 2002; 49(48):1636-8. PubMed ID: 12397752 [TBL] [Abstract][Full Text] [Related]
3. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy. Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403 [TBL] [Abstract][Full Text] [Related]
4. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Shiratori Y; Ito Y; Yokosuka O; Imazeki F; Nakata R; Tanaka N; Arakawa Y; Hashimoto E; Hirota K; Yoshida H; Ohashi Y; Omata M; Ann Intern Med; 2005 Jan; 142(2):105-14. PubMed ID: 15657158 [TBL] [Abstract][Full Text] [Related]
5. Effectiveness of interferon therapy for reducing the incidence of hepatocellular carcinoma among patients with type C chronic hepatitis. Inoue A; Tsukuma H; Oshima A; Yabuuchi T; Nakao M; Matsunaga T; Kojima J; Tanaka S J Epidemiol; 2000 Jul; 10(4):234-40. PubMed ID: 10959605 [TBL] [Abstract][Full Text] [Related]
6. Benefit of interferon therapy in hepatocellular carcinoma prevention for individual patients with chronic hepatitis C. Yoshida H; Tateishi R; Arakawa Y; Sata M; Fujiyama S; Nishiguchi S; Ishibashi H; Yamada G; Yokosuka O; Shiratori Y; Omata M Gut; 2004 Mar; 53(3):425-30. PubMed ID: 14960528 [TBL] [Abstract][Full Text] [Related]
7. Natural course of asymptomatic hepatitis C virus-infected patients and hepatocellular carcinoma after interferon therapy. Okanoue T; Minami M; Makiyama A; Sumida Y; Yasui K; Itoh Y Clin Gastroenterol Hepatol; 2005 Oct; 3(10 Suppl 2):S89-91. PubMed ID: 16234069 [TBL] [Abstract][Full Text] [Related]
8. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Shiratori Y; Imazeki F; Moriyama M; Yano M; Arakawa Y; Yokosuka O; Kuroki T; Nishiguchi S; Sata M; Yamada G; Fujiyama S; Yoshida H; Omata M Ann Intern Med; 2000 Apr; 132(7):517-24. PubMed ID: 10744587 [TBL] [Abstract][Full Text] [Related]
9. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370 [TBL] [Abstract][Full Text] [Related]
10. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)]. Yoshida H; Omata M Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842 [No Abstract] [Full Text] [Related]
11. Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepatitis C virus in Japan. Toyoda H; Tada T; Takaguchi K; Senoh T; Shimada N; Hiraoka A; Michitaka K; Ishikawa T; Kumada T J Viral Hepat; 2017 Jun; 24(6):472-476. PubMed ID: 27983762 [TBL] [Abstract][Full Text] [Related]
12. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. Okanoue T; Itoh Y; Minami M; Sakamoto S; Yasui K; Sakamoto M; Nishioji K; Murakami Y; Kashima K J Hepatol; 1999 Apr; 30(4):653-9. PubMed ID: 10207807 [TBL] [Abstract][Full Text] [Related]
13. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Imai Y; Kawata S; Tamura S; Yabuuchi I; Noda S; Inada M; Maeda Y; Shirai Y; Fukuzaki T; Kaji I; Ishikawa H; Matsuda Y; Nishikawa M; Seki K; Matsuzawa Y Ann Intern Med; 1998 Jul; 129(2):94-9. PubMed ID: 9669992 [TBL] [Abstract][Full Text] [Related]
14. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus. Tateyama M; Yatsuhashi H; Taura N; Motoyoshi Y; Nagaoka S; Yanagi K; Abiru S; Yano K; Komori A; Migita K; Nakamura M; Nagahama H; Sasaki Y; Miyakawa Y; Ishibashi H J Gastroenterol; 2011 Jan; 46(1):92-100. PubMed ID: 20711614 [TBL] [Abstract][Full Text] [Related]
15. Long-term clinical outcome and effect of glycyrrhizin in 1093 chronic hepatitis C patients with non-response or relapse to interferon. Veldt BJ; Hansen BE; Ikeda K; Verhey E; Suzuki H; Schalm SW Scand J Gastroenterol; 2006 Sep; 41(9):1087-94. PubMed ID: 16938723 [TBL] [Abstract][Full Text] [Related]
16. [Hepatitis C: epidemiology and therapy--with special reference to long-term prognosis after IFN therapy]. Fujiyama S; Tanaka M Rinsho Byori; 2000 Jan; 48(1):5-13. PubMed ID: 10756668 [TBL] [Abstract][Full Text] [Related]
17. Effect of sustained virologic response on the incidence of hepatocellular carcinoma in patients with HCV cirrhosis. Cheinquer N; Cheinquer H; Wolff FH; Coelho-Borges S Braz J Infect Dis; 2010; 14(5):457-61. PubMed ID: 21221473 [TBL] [Abstract][Full Text] [Related]
18. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. Ikeda K; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Tsubota A; Arase Y; Murashima N; Chayama K; Kumada H J Gastroenterol Hepatol; 2001 Apr; 16(4):406-15. PubMed ID: 11354279 [TBL] [Abstract][Full Text] [Related]
19. Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis. Masuzaki R; Yoshida H; Omata M Oncology; 2010 Jul; 78 Suppl 1():17-23. PubMed ID: 20616579 [TBL] [Abstract][Full Text] [Related]
20. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Janjua NZ; Chong M; Kuo M; Woods R; Wong J; Yoshida EM; Sherman M; Butt ZA; Samji H; Cook D; Yu A; Alvarez M; Tyndall M; Krajden M J Hepatol; 2017 Mar; 66(3):504-513. PubMed ID: 27818234 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]